Imperial College London
Portrait Picture

ProfessorSanjayPrasad

Faculty of Medicine, National Heart & Lung Institute

Professor of Cardiomyopathy
 
 
 
//

Contact

 

+44 (0)20 7352 8121s.prasad

 
 
//

Location

 

CMR UnitRoyal BromptonRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{UK:2024:10.1136/heartjnl-2023-323049,
author = {UK, HFpEF Collaborative Group},
doi = {10.1136/heartjnl-2023-323049},
journal = {Heart},
pages = {359--365},
title = {Rationale and design of the United Kingdom Heart Failure with Preserved Ejection Fraction Registry.},
url = {http://dx.doi.org/10.1136/heartjnl-2023-323049},
volume = {110},
year = {2024}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - OBJECTIVE: Heart failure with preserved ejection fraction (HFpEF) is a common heterogeneous syndrome that remains imprecisely defined and consequently has limited treatment options and poor outcomes. METHODS: The UK Heart Failure with Preserved Ejection Fraction Registry (UK HFpEF) is a prospective data-enabled cohort and platform study. The study will develop a large, highly characterised cohort of patients with HFpEF. A biobank will be established. Deep clinical phenotyping, imaging, multiomics and centrally held national electronic health record data will be integrated at scale, in order to reclassify HFpEF into distinct subgroups, improve understanding of disease mechanisms and identify new biological pathways and molecular targets. Together, these will form the basis for developing diagnostics and targeted therapeutics specific to subgroups. It will be a platform for more effective and efficient trials, focusing on subgroups in whom targeted interventions are expected to be effective, with consent in place to facilitate rapid recruitment, and linkage for follow-up. Patients with a diagnosis of HFpEF made by a heart failure specialist, who have had natriuretic peptide levels measured and a left ventricular ejection fraction >40% are eligible. Patients with an ejection fraction between 40% and 49% will be limited to no more than 25% of the cohort. CONCLUSIONS: UK HFpEF will develop a rich, multimodal data resource to enable the identification of disease endotypes and develop more effective diagnostic strategies, precise risk stratification and targeted therapeutics. TRIAL REGISTRATION NUMBER: NCT05441839.
AU  - UK,HFpEF Collaborative Group
DO  - 10.1136/heartjnl-2023-323049
EP  - 365
PY  - 2024///
SP  - 359
TI  - Rationale and design of the United Kingdom Heart Failure with Preserved Ejection Fraction Registry.
T2  - Heart
UR  - http://dx.doi.org/10.1136/heartjnl-2023-323049
UR  - https://www.ncbi.nlm.nih.gov/pubmed/37827557
VL  - 110
ER  -
Download